Cargando…

Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy

BACKGROUND: Oral immunotherapy containing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) (Palforzia [Aimmune Therapeutics, Brisbane, Calif]) for 9 to 12 months resulted in higher tolerated amounts of peanut protein in PTAH-treated individuals aged 4 to 17 years with peanut allergy than in pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bird, J. Andrew, Nilsson, Caroline, Brown, Kari, Pham, Trinh, Tilles, Stephen, du Toit, George, Assa’ad, Amal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509957/ https://www.ncbi.nlm.nih.gov/pubmed/37779517 http://dx.doi.org/10.1016/j.jacig.2023.100120

Ejemplares similares

Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice
por: Portnoy, Jay, et al.
Publicado: (2022)

Oral immunotherapy for peanut allergy: The pro argument
por: Chinthrajah, R. Sharon, et al.
Publicado: (2020)

Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
por: Fernandez‐Rivas, Montserrat, et al.
Publicado: (2021)

Oral immunotherapy for peanut allergy: The con argument
por: Fiocchi, Alessandro, et al.
Publicado: (2020)

Peanut allergy: Beyond the oral immunotherapy plateau
por: Bruton, Kelly, et al.
Publicado: (2021)

Peanut Immunotherapy: Stepping Towards Desensitization for Peanut Allergy
por: Hsu, Joyce
Publicado: (2020)

157 Evaluating Interest in Clinical Trial Participation for the Treatment of Pediatric Food Allergy
por: Catlin, Perry A., et al.
Publicado: (2022)

Adjuvanted Immunotherapy Approaches for Peanut Allergy
por: Johnson-Weaver, Brandi T., et al.
Publicado: (2018)

Oral Peanut Challenge Identifies an Allergy but the Peanut Allergen Threshold Sensitivity Is Not Reproducible
por: Glaumann, Susanne, et al.
Publicado: (2013)

Accidental exposures to peanut in a large cohort of Canadian children with peanut allergy
por: Cherkaoui, Sabrine, et al.
Publicado: (2015)

Peanut, soy, and emerging legume allergy in Canada
por: Cosyns, Josie C.E., et al.
Publicado: (2022)

What is new in the treatment of eosinophilic eosophagitis?
por: Assa'ad, Amal
Publicado: (2011)

Three cases with three different causes of lip and mouth swelling
por: Assa'ad, Amal
Publicado: (2015)

Mouse strain differences in response to oral immunotherapy for peanut allergy
por: Wagenaar, Laura, et al.
Publicado: (2019)

Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States
por: Blaiss, Michael S, et al.
Publicado: (2021)

Risk factors associated with safety of preschool peanut oral immunotherapy
por: Karunakaran, Duva, et al.
Publicado: (2023)

The global burden of illness of peanut allergy: A comprehensive literature review
por: Lieberman, Jay A., et al.
Publicado: (2021)

Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel
por: Togias, Alkis, et al.
Publicado: (2017)

Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel
por: Togias, Alkis, et al.
Publicado: (2017)

Bronchial hyperresponsiveness and asthma during oral immunotherapy for egg or peanut allergy in children
por: Burman, Janne, et al.
Publicado: (2022)

Baseline Gastrointestinal Eosinophilia Is Common in Oral Immunotherapy Subjects With IgE-Mediated Peanut Allergy
por: Wright, Benjamin L., et al.
Publicado: (2018)

A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents
por: van der Heiden, Marieke, et al.
Publicado: (2020)

A novel peanut allergoid is safe and effective in immunotherapy in a peanut allergy mouse model
por: Smit, J, et al.
Publicado: (2013)

Accurate and reproducible diagnosis of peanut allergy using epitope mapping
por: Suárez‐Fariñas, Mayte, et al.
Publicado: (2021)

2078- Immunotherapy – 2078. Allergen-specific oral immunotherapy for peanut allergy: a Cochrane systematic review
por: Nurmatov, Ulugbek, et al.
Publicado: (2013)

Basophil allergen threshold sensitivity, and peanut allergen components in relation to DBPCFC in children with suspected peanut allergy
por: Nilsson, Caroline, et al.
Publicado: (2011)

Efficacy and safety of oral immunotherapy for peanut allergy: a pilot study in Singaporean children
por: Zhong, Youjia, et al.
Publicado: (2018)

Qualitative interviews to understand health care providers’ experiences of prescribing licensed peanut oral immunotherapy
por: Anagnostou, Aikaterini, et al.
Publicado: (2022)

Defining the window of opportunity and target populations to prevent peanut allergy
por: Roberts, Graham, et al.
Publicado: (2023)

Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers
por: Gallop, Katy, et al.
Publicado: (2022)

Peanut Allergy: An Overview
por: Al-Ahmed, Nasser, et al.
Publicado: (2008)

Peanut allergy may be overdiagnosed in younger siblings of those with confirmed peanut allergy
por: Lavine, Elana, et al.
Publicado: (2014)

Peanut oral immunotherapy may improve health‐related quality of life among severe peanut allergic adolescents
por: Ödling, Maria, et al.
Publicado: (2023)

The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow’s milk- and peanut allergy models
por: Vonk, Marlotte M., et al.
Publicado: (2017)

Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses
por: Logan, Kirsty, et al.
Publicado: (2022)

A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy
por: Sharma, Vibha, et al.
Publicado: (2020)

Subcutaneous Immunotherapy in Patients with Fagales Pollen-Induced Oral Allergy Syndrome
por: Kong, Nasil, et al.
Publicado: (2019)

Developing Therapies for Peanut Allergy
por: Bublin, Merima, et al.
Publicado: (2014)

The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults
por: Mäntylä, Jarkko, et al.
Publicado: (2018)

JAK1 inhibition with abrocitinib decreases allergen-specific basophil and T-cell activation in pediatric peanut allergy
por: Ramsey, Nicole, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qnl9balhqrtdtr6pt1jnmeuqb5